Streetbeat News

XRTX

XORTX Therapeutics Inc.

https://www.xortx.com

Industry

Biotechnology

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Open

1.32

Mkt cap

4.8M

Volume

7.8K

High

1.39

P/E Ratio

-3.48

52-wk high

7.00

Low

1.25

Div yield

N/A

52-wk low

1.09

XORTX Therapeutics shares declined following the announcement of a securities purchase agreement with institutional investors to sell 810,810 shares of common stock at $1.85 per share.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 4:57 pm

XORTX has entered into securities purchase agreements with institutional investors for the purchase and sale of 810,810 shares at $1.85 per common share.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:08 pm

MongoDB shares surged 15.2% in pre-market trading after reporting better-than-expected Q2 earnings and strong guidance. Other notable pre-market movers include Brenmiller Energy, Focus Universal, and Emergent BioSolutions among gainers, while Elastic and Ulta Beauty are among the decliners.

Portfolio Pulse from Avi Kapoor

August 30, 2024 | 9:42 am

U.S. stocks rose with the Nasdaq surging over 1% as Best Buy reported strong earnings, raising its FY25 guidance. Best Buy's stock gained after beating EPS and sales expectations. Other notable stock movements included BioCardia, Innovative Eyewear, and XORTX Therapeutics, which saw significant gains, while iLearningEngines, Ensysce Biosciences, and Big Lots experienced declines.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 4:19 pm

U.S. stocks rose with the Dow gaining over 100 points. Nvidia reported strong earnings and announced a $50 billion stock repurchase. BioCardia and Innovative Eyewear shares surged after positive news, while iLearningEngines and Big Lots faced declines due to negative reports.

Portfolio Pulse from Avi Kapoor

August 29, 2024 | 2:00 pm

Science Applications International Corporation (SAIC) shares fell over 10% after reporting Q4 fiscal 2024 earnings below estimates, despite beating revenue consensus. Other stocks experienced significant movements, with Canoo Inc. (GOEV) surging 95% after its facility was approved as a Foreign Trade Zone, and various companies seeing gains due to positive developments or analyst upgrades. Conversely, several companies faced declines due to disappointing financial results, regulatory issues, or strategic decisions.

Portfolio Pulse from Avi Kapoor

March 18, 2024 | 6:37 pm

SOPHiA GENETICS shares fell by 19% after reporting Q4 earnings below expectations and issuing weak 2024 guidance. Other stocks showed significant movement, with Sunshine Biopharma, Airship AI Holdings, and AeroVironment among the top gainers, while Quoin Pharmaceuticals, Crawford & Company, and Ekso Bionics led the losers.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 6:11 pm

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has announced the completion of a second tranche closing, raising CAD $224,850 through a prospectus supplement and a concurrent private placement. This funding is part of a previously announced offering aimed at developing therapies for progressive kidney disease. The private placement included international subscribers, contributing CAD $99,000 to the total raised funds.

Portfolio Pulse from Charles Gross

March 04, 2024 | 12:21 pm

Mobileye Global Inc. (MBLY) shares plummeted over 23% after issuing preliminary FY23 financial results and initial 2024 guidance, which were below the previous implied guidance. Wolfe Research analyst Shreyas Patil downgraded the stock from Outperform to Peer Perform. Other stocks experienced significant movement in Thursday's mid-day session, with various companies reporting gains due to positive developments, collaborations, and strategic reviews, while others faced declines due to public offerings, corporate updates, and preliminary financial results.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 6:37 pm

XORTX Therapeutics shares have seen an increase in their trading value following an endorsement from Alliance Global Partners, which maintained a Buy rating and increased the price target for the stock from $9 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.